Media ReleasesAuscann Group Holdings

View All Auscann Group Holdings News


AusCann, Quarterly Activities Report and Appendix 4C Quarter ended December 2018

AusCann advances the development of cannabinoid hard shell capsules

Highlights

• Agreement with PCI Pharma to manufacture AusCann’s cannabinoid hard shell capsules

• DayaCann and Khiron Life Sciences to commence first cultivation activities under the MoU signed at the start of the Quarter

• Expanded medical educational program to drive engagement with medical practitioners in Australia

• CEO transition to support AusCann’s next phase of growth as a pharmaceutical company continued to progress and is now at an advanced stage

• AusCann on track for the production of cannabinoid medicines for use in clinical trials during this calendar year

31 January 2019 – Leading medical cannabis company AusCann Group Holdings Limited (ASX:AC8) (‘AusCann’ or ‘the Company’) is pleased to provide an overview of its activities for the three months ended 31 December 2018.


For further information please download PDF attached:
Download this document